ASX Briefs...everything...in three bullet points

IMPEDIMED LIMITED (ASX: IPD)

Cigna, a top five national payor, has published a medical policy covering bioimpedance spectroscopy (BIS) testing for individuals at risk for limb lymphoedema.
This policy provides coverage for over 16 million Cigna members in the US and expands coverage beyond breast cancer-related lymphoedema to all individuals at risk.
This is a significant milestone in ImpediMed's reimbursement strategy and adds to the growing momentum of their commercial effort.

2023-07-19 09:51:00

ImpediMed Limited has achieved critical reimbursement coverage of its SOZO Digital Health Platform for lymphedema testing in the state of Michigan, with over 80% of the state's insured population having access. This includes Blue Cross Blue Shield of Michigan supporting testing using SOZO.
With the achievement, there's a large available market in Michigan and existing customers include significant health systems such as Ascension Health, Corewell Health, Trinity Health, and the University of Michigan. Authorization is not required for SOZO measurements which simplifies the reimbursement process.
A significant part of ImpediMed's strategy is gaining broad national coverage through large regional Payors, with BCBS Michigan being a pivotal step. The company projects nearly all Private Payors to publish coverage by the end of the fiscal year 2024.

2023-06-29 09:32:00

Blue Cross Blue Shield of Tennessee published the first BIS-only medical policy covering testing using SOZO for cancer patients at risk for limb lymphoedema.
The policy specifically names SOZO and L-Dex, identifying BIS as medically necessary when medical appropriateness criteria are met, based on NCCN Guidelines for Survivorship.
This policy is expected to support the Private Payor payment and testing protocol assumptions used in customer return on investment (ROI) models for SOZO.

2023-06-20 12:12:00

ImpediMed announces that Florida Blue, a Blue Cross Blue Shield health plan, will cover bioimpedance spectroscopy (BIS) testing using L-Dex technology for lymphoedema assessment.
This is the first BCBS plan to publish a medical policy for L-Dex and could influence medical policy decisions by other BCBS companies, which insure 1 in 3 Americans.
ImpediMed projects 50% of private payors to publish coverage by the end of 2023 and nearly all by the end of the fiscal year 2024.

2023-06-05 08:59:00

Priority Health in Michigan published the first medical policy covering bioimpedance spectroscopy (BIS) testing using ImpediMed's SOZO for lymphoedema in breast cancer patients and survivors.
The reimbursement rate for SOZO under the policy is expected to be more than 50% higher than the current national average for Medicare reimbursement, with testing frequency based on medical necessity.
ImpediMed projects nearly 50% of Private Payors to publish coverage by the end of 2023 and nearly all Private Payors to publish coverage by the end of the fiscal year 2024.

2023-05-25 09:25:00

ImpediMed announces A$20 million institutional placement to raise funds and accelerate Private Payor opportunity and the rollout of SOZO® systems in the U.S.
Continued focus on expanding private insurance reimbursement coverage of SOZO® testing for breast cancer lymphoedema, with nearly 50% of Private Payors expected to publish policies by the end of 2023.
A non-underwritten share purchase plan will be offered to eligible shareholders in Australia and New Zealand, aiming to raise up to A$5 million.

2023-05-19 09:20:00

ImpediMed's SOZO Pro has received FDA clearance, offering improved features such as an integrated weight scale, higher weight capacity, and enhanced stand design.
The clearance allows for a Traditional 510(k) application submission to cover the heart failure indication and removal of contraindication for patients with pacemakers and ICDs.
SOZO Pro is expected to launch in the 2024 fiscal year, further accelerating expansion in oncology and additional markets like heart failure.

2023-05-05 08:19:00

The National Comprehensive Cancer Network (NCCN) has included bioimpedance spectroscopy (BIS) as an objective measurement tool to identify early signs of lymphoedema in its clinical practice guidelines for survivorship.
The NCCN recommends that cancer survivors at risk of lymphoedema undergo regular screening via symptom assessment, clinical exam, and if available, BIS.
ImpediMed has the only FDA-cleared BIS technology for the assessment of lymphoedema, and the inclusion of BIS in the NCCN guidelines will help establish it as a standard of care and accelerate adoption by private payers and providers.

2023-03-27 09:50:00